Introduction
During recent decades the number of anti-cancer drugs has grown dramatically, paralleled by an increasing number of patients receiving such therapy. These patients are frequently subjected to elective and emergency surgery. Therefore, it is incumbent upon the anaesthetist to have a clear understanding of the actions, interactions, and toxicity of anti-cancer chemotherapeutic drugs.
In principle, treatment with anti-cancer chemotherapeutic agents is intended to selectively destroy malignant cells by interfering with metabolic pathways which ideally are not present in normal cells. Such selectivity is usually directed towards neoplastic cells in division, but is difficult to achieve because the cytotoxic effects of anti-cancer chemotherapeutic agents on neoplastic and normal cells are sometimes mediated through various mechanisms of enzyme inhibition [1] . Since various side-effects of anti-cancer chemotherapy drugs may result in relevant organ toxicity, there are some facts which the anaesthetist should be aware of in (previous) cancer patients [2] . This review will not entirely deal with the problem of cell toxicity by anti-cancer chemotherapeutic agents but will focus on their organ effects and drug interactions which are of major interest for the anaesthetist. In this context, anthracyclines and bleomycin deserve special attention.
Anti-cancer chemotherapeutics
In general, anti-cancer chemotherapeutic agents may be classified as alkylating agents, anti-metabolites, plant alkaloids, antibiotics, hormones, and miscellaneous agents. The various anti-cancer drugs and their organ toxicity are summarized in Table 1 .
Alkalyting agents
Alkylating agents are chemically diverse compounds which exert their cytotoxic effects predominantly by alkylating nucleic acids. The most commonly used substances are mechlorethamine, busulfan, chlorambucil, cyclophosphamide, melphalan, and thiotepa. Bone-marrow suppression represents the most important dose-limiting factor [3] . In susceptible tumours, a rapid destruction of bulky tumour mass can produce increased purine and pyrimidine breakdown, leading to uric acid nephropathy [3] . Alkylating agents bear the potential for pneumonitis and pulmonary fibrosis [3] (carmustine, cyclophosphamide), cardiac toxicity (myocardial depression, arrhythmias; cyclophosphamide, ifosfamide, mitomycin), inhibition of plasma cholinesterase (cyclophosphamide) CNS, central nervous system; PNS, peripheral nervous system; 1, anti-cholinesterase effect; 2, inappropriate anti diuretic hormone (ADH) secretion; 3, haemorrhagic cystitis; 4, adrenocorticoid-like activity; 5, hypercalcaemia; 6, red urine.
causing a prolonged effect of succinylcholine, haemorrhagic cystitis (ifosfamide), renal insufficiency (cisplatin, ifosfamide), and peripheral neuropathy (cisplatin).
Anti-metabolites
Anti-metabolites are generally structural analogues of normal metabolites required for cell function and replication. In general, anti-metabolites interact directly with specific enzymes, leading to inhibition of that enzyme and a subsequent synthesis of an aberrant molecule that cannot function normally [3] . The following agents have been adopted for clinical use (metabolites in parentheses): methotrexate (folic acid A), mercaptopurin and thioguanin (purin A), fluorouracil (pyrimidin A), cytarabin (pyrimidine nucleoside A), and 5-azacytidine (cytidine A). Owing to their myelodepressive effects these agents are used principally for treatment of various types of leukaemia. The main side effects are mucositis including enteritis (fluorouracil, methotrexate), myocardial ischemia due to vasospasm (fluorouracil), cerebellar ataxia (fluorouracil), encephalopathy (methotrexate), renal insufficiency (methotrexate), and interstitial pneumonitis (methotrexate).
Hormones
In general, hormonal agents, agonists, or antagonists possess only little toxicity. Patients treated with agents having glucocorticoid effects require substitution during the peri-operative period.
Plant alkaloids
The anti-tumour effects of plant alkaloids (vincristine, vinblastine, etoposide, docetaxel, paclitaxel) seem to be caused by binding to critical intracellular microtubular proteins, causing mitotic arrest, and by complex reactions on nucleic acid and protein synthesis [3] . Major clinical side effects are leukopenia and neurotoxicity, evidenced by encephalopathy, peripheral-nervous-system neuropathic changes (mixed sensory and motor system), and autonomic nervous system toxicity.
Antibiotics
The tumouricidal effect is produced by formation of relatively stable complexes with DNA, thereby inhibiting DNA or RNA synthesis (inhibition of topoisomerases necessary for transcription), or both [3] . Major toxicity relates to cardiac toxicity (daunorubicin, doxorubicin, idarubicin, mixantrone), myelosuppression (doxorubicin, mitomycin, mitoxantrone), and pulmonary fibrosis (bleomycin).
Organ toxicity of chemotherapeutic drugs
As mentioned above, the various anti-cancer drugs may be associated with different organ toxicities. Since they are of major interest for the anaesthetist, toxic effects to the heart, lungs, liver, and central nervous system will be discussed in detail.
Cardiac toxicity
Cytostatic antibiotics of the anthracycline class are the best-known chemotherapeutic agents that cause cardiotoxicity. Alkylating agents such as cyclophosphamide, ifosfamide, cisplatin, carmustine, busulfan, chlormethine, and mitomycin have also been associated with cardiotoxicity. Other agents that may induce a cardiac event include paclitaxel, etoposide, teniposide, the vinca alkaloids, fluorouracil, cytarabine, amsacrine, cladribine, L-asparaginase, tretinoin, and pentostatin. Cardiotoxicity is rare with some agents, but may occur in >20% of patients treated with doxorubicin, daunorubicin, or fluorouracil [4] .
Cardiac events may include mild blood-pressure changes, thrombosis, electrocardiographic changes, (acute) arrhythmias, myocarditis, pericarditis, myocardial infarction, cardiomyopathy, reduced (systolic) left-ventricular function, and congestive (left-ventricular) heart failure. Electrocardiogram changes are common; ST-T alterations or dysrhythmias may occur in up to 40% of patients [4] . Furthermore, QTc prolongation (corrected QT interval), which is associated with potentially lethal arrhythmias such as polymorphic ventricular tachycardia and ventricular fibrillation, is a marker of post-anthracycline cardiotoxicity [5, 6] . For doxorubicin, a dose-dependent increase in QTc interval has been shown [5] .
Various arrhythmias have been reported with the administration of anti-cancer drugs. The spectrum comprises bradyarrhythmias, including complete heart block (paclitaxel) and supra-and ventricular arrhythmias (anthracyclines, ifosfamide, fluorouracil, interferon). Angina and ischemic electrocardiogram changes have been well described, with the administration of fluorouracil for 10% of patients evidence of acute myocardial infarction [7] .
Clinical cardiotoxicity after anti-cancer chemotherapy comprises both an early cardiotoxicity (during or shortly after treatment, within days or weeks after treatment) and a late cardiotoxicity, which may not be apparent until months, and sometimes years, after completed chemotherapy. So far, delayed cardiotoxicity has been seen only after anthracycline therapy. However, patients receiving any cardiotoxic agent should be followed after completion of treatment.
A number of risk factors may predispose a patient to cardiotoxicity. These are cumulative dose (anthracyclines, mitomycin), total dose administered during a day of a course (cyclophosphamide, ifosfamide, carmustine, fluorouracil, cytarabine), rate of administration (anthracyclines, fluorouracil), schedule of administration (anthracyclines), mediastinal radiation, age, female gender, concurrent administration of cardiotoxic agents, previous anthracycline chemotherapy, history of pre-existing cardiovascular disorders, and electrolyte imbalances such as hypokalaemia and hypomagnesiaemia [8] [9] [10] [11] [12] .
In general, the risk of congestive heart failure for children who have received a cumulative anthracycline dose of 100-399 mg/m 2 is 1.7% as compared with a risk of 9% at cumulative doses of >500 mg/m 2 [13] . Despite attempts to reduce cardiotoxicity by limiting the cumulative dose, abnormalities in cardiac structure and function were noted in 65% of survivors of childhood acute lymphoblastic leukaemia 6 years after completed anthracycline therapy [14] . In this population, early congestive heart failure is the strongest risk factor for peri-operative cardiovascular complications with subsequent surgical procedures [15] . Recently, it has been shown that, in survivors of childhood cancer, subtle abnormalities in cardiac function may exist, even in patients with normal resting cardiac function, which become apparent only after exercise. Patients with anthracycline treatment showed a significantly smaller increase in fractional shortening, a marker of left-ventricular systolic function, after exercise compared with patients without such treatment [16, 17] . Chronic cardiotoxic congestive heart failure is cumulative and dose-relevant and does usually not respond to digitalis therapy. Frequency of serious cardiomyopathy is 1-10% and increases markedly with dose, irradiation, or when an anthracycline is given concomitantly with other cytostatic drugs. Mortality rate of chronic cardiotoxic failure is in excess of 50% [18] . Although not frequent, these manifestations are serious.
Clinical experience
In general, clinical data on anaesthesia and anthracyclines are scarce. In a study analysing the 111 anaesthetic records of 68 patients with an age between 0.5 and 22 years, seven (6.3%) cardiovascular complications (hypotension) were identified. Myocardial dysfunction could be diagnosed in two patients by increase in pulmonary arterial occlusion pressure with unchanged right-heart filling pressures. In this study, induction techniques comprised inhalation of halothane and intravenous application of thiopentone, diazepam, and ketamine, and maintenance technique comprised halothane, enflurane, and N 2 O. However, no particular anaesthetic technique could be identified as a risk factor [15] . In another study, 14 anthracycline-treated patients undergoing laparotomy for ovarian cancer under general anaesthesia were maintained with 70% N 2 O in O 2 and assigned randomly to either isoflurane (0.6% end-tidal) or fentanyl (2.6 mg/kg loading dose, 7.2 mg/kg total dose). No complications occurred; the isoflurane group showed a better haemodynamic stability and smaller changes in cardiac index, systemic vascular resistance, and base excess [19] . Gorton et al. [20] reported two women with elective Caesarian section who had received anti-cancer chemotherapy with anthracyclines during childhood. While pre-operative echocardiography revealed a reduced left-ventricular systolic function in both patients, only one of them had clinical signs of heart failure (i.e. shortness of breath). In both patients, spinal anaesthesia was performed. Despite a short phase of hypotension, which required ephedrine administration in both patients, no intra-operative invasive haemodynamic monitoring became necessary and the further clinical course was uneventful. Recently, Owczuk et al. [21] . At baseline, both groups had similar cardiac function, i.e. fractional shortening was 34.9 AE 3.7 (anthracycline) versus 34.1 AE 3.7 (control); however, fractional shortening changed to 24.1 AE 3.2 (anthracycline) versus 28.2 AE 2.5 (control; P < 0.01) at 20 min after induction of anaesthesia (Fig. 1) . Accordingly, stroke-volume index fell from 36 AE 6 ml/m 2 (anthracycline) versus 35 AE 4 ml/m 2 (control; not significant) at baseline to 26 AE 6 ml/m 2 (anthracycline) versus 31 AE 5 ml/m 2 (control; P < 0.01). In individual patients the decrease in fractional shortening reached almost 50% compared to baseline. In this investigation almost no correlation was found between the accumulative dose of anthracycline and abnormalities of cardiac function during anaesthesia. In conclusion, previous treatment with anthracyclines may enhance the myocardial-depressive effect of anaesthetics even in patients with a normal cardiac function at rest.
Pulmonary toxicity
The field of respiratory adverse effects comprises an early inflammatory interstitial pneumonitis (methotrexate, bleomycin, paclitaxel, docetaxel, busulphan, mitomycin, procarbazine, carmustine), acute non-cardiogenic pulmonary oedema (arabinoside, bleomycin, interleukin-2), bronchospasm (vinblastine, methotrexate), and pleural effusion (methotrexate). Depending on the agent and population, the incidence varies from 1 to 25%. Late-onset disease is more common and usually manifests as pulmonary fibrosis (bleomycin, busulfan, carmustine, mitomycin) [3] . Most notably, there may be a high incidence of clinically silent lung injury. The toxicity may be monitored by the decrease in diffusion capacity for carbon monoxide (>10-15% from baseline), which has been found to be the most sensitive indicator of subclinical pulmonary damage from chemotherapeutics [23] . In a prospective clinical study, paclitaxel and carboplatin led to significant but clinically silent decrease (!20% of start values) in diffusion capacity for carbon monoxide, persisting for 5 months after completion of chemotherapy [24] .
Among the various agents, bleomycin is of special interest to the anaesthetist, since bleomycin is the most important cause of pulmonary toxicity which may lead to pulmonary fibrosis. Bleomycin produces pulmonary toxic effects in 2-40% of patients receiving the drug [25] . The toxicity of bleomycin is, in short, related to a damage of the pulmonary endothelium leading to increased permeability, interstitial oedema, and necrosis of type I alveolar epithelium (pneumocytes), which may finally cause pulmonary fibrosis in case of inadequate repair due to high or repeated drug exposure. Factors that can increase the risk of bleomycin-induced lung damage are age >70 years, increased total dose (>450 mg), the presence of renal failure (creatinine clearance <35 ml/min), and radiation therapy.
A controversial question is the issue of provoking lung injury by high inspiratory oxygen fractions (F i O 2 ) even months or years after drug exposure, as bleomycinassociated lung injury is mediated via oxidant pathways. In animal models, hyperoxia exposure shortly after bleomycin administration synergistically increases its pulmonary toxicity [26] [27] [28] . In contrast, delayed exposure is not harmful [29] [30] [31] [32] [33] .
In humans, case reports demonstrate that a short interval between bleomycin administration and hyperoxia may increase the risk of respiratory failure [34, 35] . In case of a delayed oxygen exposure, i.e. after months or years, there is little if any evidence that high inspiratory oxygen fractions may lead to further pulmonary damage. There is only one retrospective case series, in which patients had documented restrictive lung disease as shown by decreased carbon monoxide diffusion capacity secondary to bleomycin treatment: patients with an average F i O 2 of 39% developed post-operative acute respiratory distress syndrome and died of respiratory failure [36] . However, these findings could not be supported by further studies [37, 38] . Thus, pre-existing bleomycin-associated lung damage, as shown by pulmonary function tests, may be a key factor in the risk of hyperoxia lung injury with bleomycin.
Another potential risk factor may be a genetic predisposition towards bleomycin toxicity as well as to bleomycin pulmonary injury from hyperoxia exposure due to varying activity levels of bleomycin hydroxylase. This enzyme deactivates the drug in the lung, providing an Anaesthesia and anti-cancer chemotherapeutic drugs Huettemann and Sakka 311 argument for a cautious use of high inspiratory oxygen fractions.
Up to 25% of patients with previous bleomycin therapy may develop post-operative respiratory insufficiency necessitating prolonged post-operative intubation of the trachea [38, 39] . Factors indicating post-operative respiratory insufficiency are excessive fluid intake, perioperative transfusion, decrease in vital capacity, and duration of surgery. As already mentioned, one should be aware that there is a high percentage of sub-clinical bleomycin-induced pulmonary damage compromising the ability of the lungs to handle large volumes of fluid. Thus, at least as important as the use of the lowest inspiratory oxygen fraction compatible with adequate tissue oxygenation are the careful management of intravenous fluid administration and the restriction of fluids (preferably colloids) to the minimum necessary to maintain haemodynamic stability and adequate renal output. For clinical practice, it seems reasonable, as in any other patient, to use the lowest inspired oxygen fraction compatible with adequate tissue oxygenation.
Renal toxicity
Several agents can cause renal impairment, and tubular and glomerular dysfunction (paclitaxel, carboplatin, cisplatin, cyclophosphamide, vincristine, ifosfamide, methotrexate), usually presenting as non-oliguric renal failure [40, 41] . Dose-related nephrotoxicity subsequent to administration of certain chloroethylnitrosourea compounds (carmustine, semustine, streptozocin) is commonly heralded by increased serum creatinine levels, uraemia and proteinuria. Additional signs of streptozocininduced nephrotoxicity include hypophosphataemia, hypokalaemia, hypouricaemia, renal tubular acidosis, glucosuria, aceturia and aminoaciduria. Further side effects are urate nephropathy due to tumour lysis, haemorrhagic cystitis and haematuria. Non-steroidal anti-inflammatory drugs may precipitate acute renal failure in combination with cytotoxic agents, especially in myeloma. These drugs should be avoided in patients receiving nephrotoxic chemotherapy.
Hepatotoxicity
Anti-neoplastic drugs can cause a wide variety of effects on the liver [42] . In addition, many of these patients may have co-existing liver disease, hepatic metastases, or infections. Many of them may also be taking other hepatotoxic medications. Mild elevation of live enzymes is a common finding, but more serious adverse effects may also result. These range from fatty liver, cholestasis, fibrosis, cirrhosis, veno-occlusive disease, and cholangitis. Life-threatening hepatic necrosis may occur with methotrexate, 6-mercaptopurine, and L-asparaginase. Intensive chemotherapy has been implicated in the development of fatal hepatic necrosis following haloalkane anaesthesia [43] . Thus, it may be prudent whenever an inhalational agent is considered to use one with only minimal metabolism, such as desflurane (dose uptake 0.02-0.2%) [44] .
Central-nervous-system toxicity Neurotoxicity can occur with a variety of agents (busulfane, paclitaxel, vincristine, cisplatin) and may be shown by encephalopathy, peripheral-nervous-system neuropathic changes (mixed sensory and motor system), and autonomic-nervous-system toxicity [3] . Cisplatin exposure causes a dose-dependent peripheral neuropathy, the incidence approaching 85% in patients receiving doses >300 mg/m 2 [45] . Thus, in a large percentage of patients receiving cisplatin a sub-clinical unrecognized neuropathy may be present. A diffuse brachial plexopathy after interscalene blockade has been reported in a patient receiving cisplatin chemotherapy. Consequently, if a regional anaesthetic is contemplated, a pre-operative detailed neurological examination and careful assessment of the risks and benefits of performing regional anaesthetic techniques is warranted [46] . Furthermore, vincristine-induced vocal-cord paralysis has been addressed in several case reports [47] [48] [49] and should be considered in the differential diagnosis when stridor develops in patients with malignancies.
Drug metabolism
Cytostatic drugs undergo bioactivation, mainly by the cytochrome P450 enzyme system in the liver and in some other tissues. However, most of the intravenous anaesthetics, such as the benzodiazepines, opioids and local anaesthetics, are metabolized by the cytochrome system as well. In plasma concentrations present during antineoplastic chemotherapy, some agents, such as docetaxel, cyclophosphamide, ifosfamide, vinblastine, and teniposide, could possibly cause clinical drug interactions due to inhibition of cytochome P450 enzymes [50] . Furthermore, barbiturates and dexamethasone, for example, are potent inducers of this enzyme group, while several other drugs (such as amiodarone or cimetidine) are potent inhibitors of the P450 enzymes. Thus, in patients with previous or ongoing chemotherapy a wide array of clinical drug interactions may occur which may as well enhance toxicity of chemotherapeutic drugs as the effect of anaesthetics [51] . As a consequence, a high level of alertness is warranted.
Anti-cancer drugs and anaesthetic interaction
Most of the studies on the interactions between anticancer chemotherapeutics and anaesthetic substances were in vitro or of an animal-experimental nature [50, 51] . In principle, anaesthetics may influence metabolism of anti-cancer chemotherapeutics and neoplastic growth per se.
In vitro, clinically achievable concentrations of the local anaesthetic procaine and lidocaine enhanced doxorubicin and bleomycin toxicity [52, 53] . In rats, the cytotoxic effect of methotrexate on proliferating cells was enhanced by N 2 O [54] . Halothane has been shown to lead to an increased cytotoxicity of cyclophosphamide in mice [55] and to potentiate the anti-tumour activity of interferon-g [56] . In an animal study investigating the delivery of chemotherapeutic drugs to brain tumour and normal brain, propofol/N 2 O anaesthesia was found to be superior to isoflurane/O 2 for optimizing osmotic bloodbrain barrier disruption. The propofol/N 2 O regimen was not associated with neurotoxicity and neuropathology. A study in rats provides evidence that benzodiazepines may also interact with anti-cancer chemotherapeutics. The combination of lonidamine, a new mitochondrial targeting anti-cancer drug, and diazepam was significantly more effective in reducing glioblastoma tumour growth than the drug alone [57] . However, the clinical relevance of these findings remains an open question.
Conclusion
When assessing patients who have previously undergone chemotherapy, the underlying disease itself, nutritional status, and effects of concurrent therapy, such as radiation, must be taken into account, since there may be alterations in organ function (haemostasis, dysproteinaemia, hypoalbuminaemia, cognitive dysfunction, immune response, compromised or difficult airway, mediastinal mass syndrome) independent of and/or in addition to the effect of anti-neoplastic agents [58] . In any case, patients who received anti-cancer chemotherapy should be evaluated carefully for evidence of (insidious) impaired cardiac, pulmonary, renal, or hepatic function. Patients with a history of chemotherapy with cardiotoxic drugs should undergo echocardiography prior to surgery. However, given our data, even in patients with a normal cardiac function at rest, pronounced cardio-depressive effects may be encountered. While in minor surgery a balanced anaesthesia technique appears safe in these patients; however, in major surgery with anticipated volume shifts and/or additional cardio-depressive factors, such as sepsis, advanced haemodynamic monitoring by invasive arterial blood-pressure measurement should be considered even in patients with normal cardiac function. In all patients, informed consent containing all treatment data and risks must be obtained before surgery. The oncologist who initiated the anti-cancer therapy should be involved in the peri-operative assessment since this colleague is an important member of the multi-disciplinary care team.
